Filosa A, Di Maio S, Aloj G, Acampora C
Pediatric Department, Cardarelli Hospital, Naples, Italy.
J Pediatr Endocrinol Metab. 2006 Dec;19(12):1397-404. doi: 10.1515/jpem.2006.19.12.1397.
Primary hypothyroidism is one of the most frequent complications observed in patients suffering from thalassemia. We investigated thyroid function in a group of patients attending the Pediatric Department of Cardarelli Hospital in order to determine in how many patients thyroid function worsened during a 12 year-period of follow up.
Fifty patients with beta-thalassemia major (27 females and 23 males), mean age 25.7+/-1.4 years, were re-evaluated according to the criteria of Faglia et al. Thyroid dysfunction was defined as follows: overt hypothyroidism (low FT4 and increased TSH levels >10 microU/ml); compensated hypothyroidism (normal FT4, TSH 5-10 microU/ml, and abnormal TRH test); subclinical hypothyroidism (normal FT4, basal TSH 0-5 microU/ml, abnormal TRH test). Correlation with hematological, biochemical and growth parameters was evaluated.
Ten out of 50 patients evaluated in a previous study had moved to other centers, and four patients had died from cardiac problems. Thus, 36 patients completed a 12 year-period of follow-up. In 25% of the patients the degree of thyroid dysfunction worsened with different degrees of severity. The prevalence of overt hypothyroidism had risen to 13.9% from 8.4%. No cases of secondary hypothyroidism were observed, and anti-thyroglobulin and anti-thyroperoxidase (TPO) antibody titers were negative in all patients. Five (28%) out of 17 patients with normal thyroid function previously (one female, four male) showed an exaggerated TSH response to a TRH test, with normal serum levels of FT4, and they were classified as having subclinical hypothyroidism; while another patient died of cardiac complications. Four out of twelve patients with previous subclinical hypothyroidism showed worsening with a different degree of severity: two females changed to compensated hypothyroidism, and two males to overt hypothyroidism. Furthermore, two out of six patients with compensated hypothyroidism and one out of four patients with overt hypothyroidism died of cardiac failure. In all patients there was no correlation between serum ferritin levels, blood transfusion, pretransfusion Hb levels and worsening of thyroid function. Echographic data showed features of dishomogeneity of the parenchyma with different degrees of severity in accordance with the criteria of Sostre and Reyes. The highest score was observed in all patients with overt and compensated hypothyroidism.
A slow worsening of thyroid function was observed in 25% of the studied patients and only two of them developed overt hypothyroidism. The echographic pattern seems to be strongly predictive of thyroid dysfunction.
原发性甲状腺功能减退是地中海贫血患者中最常见的并发症之一。我们调查了卡雷利医院儿科一组患者的甲状腺功能,以确定在12年的随访期内有多少患者的甲状腺功能恶化。
根据法利亚等人的标准,对50例重型β地中海贫血患者(27例女性和23例男性)进行了重新评估,平均年龄25.7±1.4岁。甲状腺功能障碍的定义如下:显性甲状腺功能减退(游离甲状腺素低且促甲状腺激素水平升高>10微单位/毫升);代偿性甲状腺功能减退(游离甲状腺素正常,促甲状腺激素5 - 10微单位/毫升,促甲状腺激素释放激素试验异常);亚临床甲状腺功能减退(游离甲状腺素正常,基础促甲状腺激素0 - 5微单位/毫升,促甲状腺激素释放激素试验异常)。评估了与血液学、生化和生长参数的相关性。
在之前一项研究中评估的50例患者中有10例转到了其他中心,4例患者死于心脏问题。因此,36例患者完成了12年的随访。25%的患者甲状腺功能障碍程度不同程度地恶化。显性甲状腺功能减退的患病率从8.4%升至13.9%。未观察到继发性甲状腺功能减退病例,所有患者的抗甲状腺球蛋白和抗甲状腺过氧化物酶(TPO)抗体滴度均为阴性。之前甲状腺功能正常的17例患者中有5例(1例女性,4例男性)对促甲状腺激素释放激素试验显示促甲状腺激素反应过度,游离甲状腺素血清水平正常,他们被归类为亚临床甲状腺功能减退;而另1例患者死于心脏并发症。之前亚临床甲状腺功能减退的12例患者中有4例不同程度地恶化:2例女性转变为代偿性甲状腺功能减退,2例男性转变为显性甲状腺功能减退。此外,6例代偿性甲状腺功能减退患者中有2例和4例显性甲状腺功能减退患者中有1例死于心力衰竭。在所有患者中,血清铁蛋白水平、输血情况、输血前血红蛋白水平与甲状腺功能恶化之间均无相关性。超声检查数据显示,根据索斯特雷和雷耶斯的标准,实质不均匀性具有不同程度的特征。在所有显性和代偿性甲状腺功能减退患者中观察到最高评分。
在25%的研究患者中观察到甲状腺功能缓慢恶化,其中只有2例发展为显性甲状腺功能减退。超声检查模式似乎强烈预示甲状腺功能障碍。